Currently, there are 77.01M common shares owned by the public and among those 58.08M shares have been available to trade.
The company’s stock has a 5-day price change of 1.15% and 15.67% over the past three months. REPL shares are trading 16.43% year to date (YTD), with the 12-month market performance up to 97.06% higher. It has a 12-month low price of $4.92 and touched a high of $17.00 over the same period. REPL has an average intraday trading volume of 925.82K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 4.50%, 11.37%, and 34.01% respectively.
Institutional ownership of Replimune Group Inc (NASDAQ: REPL) shares accounts for 86.38% of the company’s 77.01M shares outstanding.
It has a market capitalization of $1.09B and a beta (3y monthly) value of 1.29. The earnings-per-share (ttm) stands at -$3.14. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.86% over the week and 7.00% over the month.
Earnings per share for the fiscal year are expected to increase by 13.39%, and 2.35% over the next financial year. EPS should grow at an annualized rate of 13.91% over the next five years, compared to -19.52% over the past 5-year period.
Looking at the support for the REPL, a number of firms have released research notes about the stock. ROTH MKM stated their Buy rating for the stock in a research note on August 28, 2024, with the firm’s price target at $17. Piper Sandler coverage for the Replimune Group Inc (REPL) stock in a research note released on April 17, 2023 offered a Overweight rating with a price target of $44. Piper Sandler was of a view on November 19, 2021 that the stock is Overweight, while BTIG Research gave the stock Buy rating on October 15, 2021, issuing a price target of $60. BTIG Research on their part issued Buy rating on November 17, 2020.
